CORRELATION OF XPD/ERCC2 POLYMORPHISM WITH CLINICAL SENSITIVITY TO OXALIPLATIN-BASED CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER

Objective To observe the correlation of XPD/ERCC2 Lys751Gln (C→A,35931) genetic polymorphism with clinical outcome of oxaliplatin-based chemotherapy in patients with advanced colorectal cancer (ACC). MethodsDNA was extracted from peripheral venous blood obtained from 70 patients with stage-Ⅳ ACC before chemotherapy. Real-time PCR was used for single nucleotide polymorphism genotyping of XPD/ERCC2 gene. After oxaliplatin-based chemotherapy, objective response of tumor was compared between different genotypes.ResultsThe mutants and mutation frequency of XPD/ERCC2 Lys751Gln found in this cohort study were: C/C 55.72%, C/A 35.71% and A/A 8.57%. The effective rate of the chemotherapy the patients in this study was 54.29% (CR+PR+SD). The distribution of patients with C/C genotype and patients with C/A+A/A genotype in chemotherapy-effective group (CR+PR+SD) and non-effective group (PD) was significantly different (χ2=7.926,P0.005).ConclusionXPD/ERCC2 Lys751Gln genetic polymorphisms is associated with clinical outcome of oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.